Discovery platform for therapeutics development

Atreca’s proprietary discovery platform generates and develops therapeutics based on rapid characterization of human adaptive immune response at the single cell level. Foundation partners use the platform to isolate novel human monoclonal antibodies, gain immune response and vaccination insights, and generate new tools for global health vaccine discovery and development.
  • Domain
  • Investment type
    Direct equity
  • Status
  • Initial investment
    Series A
  • Partnered in
  • Headquarters
  • Program strategy
    Discovery & Translational Sciences

More about our work

Our focus

Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.

Investment approach

Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.

Our team

We bring depth of experience to every investment, with a proven track record across sectors and scale.